Hematologic and hepatic toxicity in 53 patients who received 2 courses of GO after randomization
| . | GO1 baseline . | GO1 nadir . | GO1 peak . | GO2 baseline . | GO2 nadir . | GO2 peak . |
|---|---|---|---|---|---|---|
| Hematologic | ||||||
| Hb, g/dL | 10.5 | 10.1 | 12.0 | 10.8 | ||
| 8.1-14.3 | 7.8-14.0 | 9.8-15.0 | 8.2-14.8 | |||
| WHO grade 3/4 (%) | 2/0 (4) | 0/0 (0) | ||||
| WBC, ×109/L | 2.7 | 0.5 | 3.7 | 0.7 | ||
| 1.5-9.8 | 0.0-4.1 | 1.6-16.8 | 0.2-4.4 | |||
| WHO grade 3/4 (%) | 7/43 (94) | 13/35 (92) | ||||
| Neutrophils, ×109/L | 1.3 | 0.0 | 1.6 | 0.0 | ||
| 0.7-8.6 | 0.0-3.2 | 0.4-13.3 | 0.0-1.4 | |||
| WHO grade 3/4 (%) | 0/50 (96) | 1/47 (96) | ||||
| Platelets, ×109/L | 199 | 83 | 238 | 62 | ||
| 43-470 | 10-239 | 97-460 | 11-202 | |||
| WHO grade 3/4 (%) | 5/3 (15) | 16/4 (39) | ||||
| Hepatic | ||||||
| ALAT, U/L | 48 | 82 | 61 | 72 | ||
| 14-204 | 20-279 | 12-121 | 21-282 | |||
| WHO grade 3/4 (%) | 2/0 (4) | 1/0 (2) | ||||
| Bilirubin, μmol/L | 5 | 8 | 5 | 7 | ||
| 2-15 | 2-28 | 1-15 | 2-36 | |||
| WHO grade 3/4 (%) | 0/0 (0) | 0/0 (0) |
| . | GO1 baseline . | GO1 nadir . | GO1 peak . | GO2 baseline . | GO2 nadir . | GO2 peak . |
|---|---|---|---|---|---|---|
| Hematologic | ||||||
| Hb, g/dL | 10.5 | 10.1 | 12.0 | 10.8 | ||
| 8.1-14.3 | 7.8-14.0 | 9.8-15.0 | 8.2-14.8 | |||
| WHO grade 3/4 (%) | 2/0 (4) | 0/0 (0) | ||||
| WBC, ×109/L | 2.7 | 0.5 | 3.7 | 0.7 | ||
| 1.5-9.8 | 0.0-4.1 | 1.6-16.8 | 0.2-4.4 | |||
| WHO grade 3/4 (%) | 7/43 (94) | 13/35 (92) | ||||
| Neutrophils, ×109/L | 1.3 | 0.0 | 1.6 | 0.0 | ||
| 0.7-8.6 | 0.0-3.2 | 0.4-13.3 | 0.0-1.4 | |||
| WHO grade 3/4 (%) | 0/50 (96) | 1/47 (96) | ||||
| Platelets, ×109/L | 199 | 83 | 238 | 62 | ||
| 43-470 | 10-239 | 97-460 | 11-202 | |||
| WHO grade 3/4 (%) | 5/3 (15) | 16/4 (39) | ||||
| Hepatic | ||||||
| ALAT, U/L | 48 | 82 | 61 | 72 | ||
| 14-204 | 20-279 | 12-121 | 21-282 | |||
| WHO grade 3/4 (%) | 2/0 (4) | 1/0 (2) | ||||
| Bilirubin, μmol/L | 5 | 8 | 5 | 7 | ||
| 2-15 | 2-28 | 1-15 | 2-36 | |||
| WHO grade 3/4 (%) | 0/0 (0) | 0/0 (0) |
Median values and ranges with WHO toxicity grade 3 and 4 are presented.
GO indicates gemtuzumab ozogamicin; Hb, hemoglobin; and ALAT, alanine aminotransferase.